- Home
- SIEB vs VTYX Comparison
SIEB vs VTYX Comparison
Compare SIEB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- VTYX
- Stock Information
- Founded
- SIEB 1886
- VTYX 2018
- Country
- SIEB United States
- VTYX United States
- Employees
- SIEB N/A
- VTYX N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SIEB Finance
- VTYX Health Care
- Exchange
- SIEB Nasdaq
- VTYX Nasdaq
- Market Cap
- SIEB 148.8M
- VTYX 154.9M
- IPO Year
- SIEB N/A
- VTYX 2021
- Fundamental
- Price
- SIEB $4.03
- VTYX $1.24
- Analyst Decision
- SIEB
- VTYX Buy
- Analyst Count
- SIEB 0
- VTYX 4
- Target Price
- SIEB N/A
- VTYX $11.33
- AVG Volume (30 Days)
- SIEB 63.9K
- VTYX 982.1K
- Earning Date
- SIEB 05-20-2025
- VTYX 05-08-2025
- Dividend Yield
- SIEB N/A
- VTYX N/A
- EPS Growth
- SIEB 57.14
- VTYX N/A
- EPS
- SIEB 0.33
- VTYX N/A
- Revenue
- SIEB $83,639,000.00
- VTYX N/A
- Revenue This Year
- SIEB N/A
- VTYX N/A
- Revenue Next Year
- SIEB N/A
- VTYX N/A
- P/E Ratio
- SIEB $11.45
- VTYX N/A
- Revenue Growth
- SIEB 17.39
- VTYX N/A
- 52 Week Low
- SIEB $1.41
- VTYX $0.78
- 52 Week High
- SIEB $3.85
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- SIEB 78.40
- VTYX 50.66
- Support Level
- SIEB $3.29
- VTYX $1.15
- Resistance Level
- SIEB $3.75
- VTYX $1.48
- Average True Range (ATR)
- SIEB 0.23
- VTYX 0.11
- MACD
- SIEB 0.03
- VTYX 0.01
- Stochastic Oscillator
- SIEB 100.00
- VTYX 44.19
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.